Angel investor and Shark Tank India judge Anupam Mittal has shared a critical perspective on the recent introduction of the drug Ozempic in the Indian market. Through a detailed LinkedIn post, Mittal addressed the international hype surrounding the medication, its potential misuse as a quick fitness fix, and a significant upcoming change in the pharmaceutical industry that could reshape the market.
The Ozempic Phenomenon: A Shortcut for Fitness Aspirations?
Mittal observed that while the desire to be fit is long-standing among Indians, the modern approach often seeks easier solutions over committed lifestyle changes. "Maybe that's why Ozempic feels like a gold injection right now," he remarked, highlighting the drug's perceived value as a shortcut. He pointed out that Ozempic, globally popular for weight loss among celebrities, is being introduced in India by its maker with a focus on diabetes care, evidence-based medicine, and responsible prescription practices.
The drug comes with a substantial cost, priced at approximately ₹8,800 per month. Mittal shared industry projections indicating that Ozempic alone could generate an annual market worth nearly ₹1,000 crore in India.
The 2026 Patent Cliff: A Game-Changer for Indian Pharma
Mittal underlined a major disruptive event on the horizon. Starting March 2026, key patents for GLP-1 drugs, the class Ozempic belongs to, are set to expire. This expiration is expected to pave the way for Indian pharmaceutical companies to introduce more affordable generic versions.
He suggested this will trigger rapid expansion in the sector. "The real plot twist lands in March '26, when GLP-1 patents begin to expire. That's when every pharma company will discover its inner weight-loss baba and the industry could 5x in a few years. Cipla looks ready to open the ashram first," Mittal wrote, indicating companies like Cipla are well-positioned to lead this charge.
A Medical Miracle, Not a Lifestyle Accessory
Despite discussing its market potential, Mittal issued a clear caution against viewing such drugs as casual lifestyle substitutes. He expressed concern that "If Ozempic becomes for fat loss what Eno is for acidity, half of urban India may be on a monthly injection plan, just to look better on Instagram."
He was emphatic in giving credit where it's due, stating these drugs are a breakthrough for specific medical conditions. "For obesity, diabetes, and serious metabolic issues, GLP-1s are genuinely life-changing. Science deserves full credit," he affirmed. However, for the average individual without a medical necessity, he argued that foundational health principles remain superior.
Mittal concluded with a punchy, relatable reminder: "Shortcuts are seductive. Science is powerful. But fitness ka jugaad nahi hota, boss. Lifestyle compounds. Discipline protects."
His post sparked reactions on social media, with users echoing the sentiment on discipline. One user commented on the need for better regulation of junk food, while another noted, "Eno for acidity. Ozempic for obesity. But no injection yet for lack of discipline. Lifestyle still undefeated." A third user simply applauded Mittal's final line as "Golden Words."
